|
1
|
Huang X, Liang M, Dittmar R and Wang L:
Extracellular microRNAs in urologic malignancies: Chances and
challenges. Int J Mol Sci. 14:14785–14799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Spronsen DJ, de Weijer KJ, Mulders PF
and De Mulder PH: Novel treatment strategies in clear-cell
metastatic renal cell carcinoma. Anticancer Drugs. 16:709–717.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hadoux J, Vignot S and De La Motte Rouge
T: Renal cell carcinoma: Focus on safety and efficacy of
temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar
|
|
6
|
Zisman A, Pantuck AJ, Wieder J, Chao DH,
Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk
group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dutcher JP: Recent developments in the
treatment of renal cell carcinoma. Ther Adv Urol. 5:338–353. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen B, Duan L, Yin G, Tan J and Jiang X:
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer
cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J
Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nie F, Liu T, Zhong L, Yang X, Liu Y, Xia
H, Liu X, Wang X, Liu Z, Zhou L, et al: MicroRNA-148b enhances
proliferation and apoptosis in human renal cancer cells via
directly targeting MAP3K9. Mol Med Rep. 13:83–90. 2016.
|
|
11
|
Gao C, Peng FH and Peng LK: MiR-200c
sensitizes clear-cell renal cell carcinoma cells to sorafenib and
imatinib by targeting heme oxygenase-1. Neoplasma. 61:680–689.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z,
Li C, Ren H, Li Y, He X, et al: miR-27b synergizes with anticancer
drugs via p53 activation and CYP1B1 suppression. Cell Res.
25:477–495. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murata T, Takayama K, Katayama S, Urano T,
Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y,
et al: miR-148a is an androgen-responsive microRNA that promotes
LNCaP prostate cell growth by repressing its target CAND1
expression. Prostate Cancer Prostatic Dis. 13:356–361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahashi M, Cuatrecasas M, Balaguer F,
Hur K, Toiyama Y, Castells A, Boland CR and Goel A: The clinical
significance of MiR-148a as a predictive biomarker in patients with
advanced colorectal cancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Song Y, Wang Y, Luo J and Yu W:
MicroRNA-148a suppresses epithelial-to-mesenchymal transition by
targeting ROCK1 in non-small cell lung cancer cells. Mol Cell
Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia J, Guo X, Yan J and Deng K: The role
of miR-148a in gastric cancer. J Cancer Res Clin Oncol.
140:1451–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujita Y, Kojima K, Ohhashi R, Hamada N,
Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T, et al:
MiR-148a attenuates paclitaxel resistance of hormone-refractory,
drug-resistant prostate cancer PC3 cells by regulating MSK1
expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liffers ST, Munding JB, Vogt M, Kuhlmann
JD, Verdoodt B, Nambiar S, Maghnouj A, Mirmohammadsadegh A, Hahn SA
and Tannapfel A: MicroRNA-148a is down-regulated in human
pancreatic ductal adenocarcinomas and regulates cell survival by
targeting CDC25B. Lab Invest. 91:1472–1479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang SH, Li X, Zhou LS, Cao ZW, Shi C,
Zhou CZ, Wen YG, Shen Y and Li JK: microRNA-148a suppresses human
gastric cancer cell metastasis by reversing
epithelial-to-mesenchymal transition. Tumour Biol. 34:3705–3712.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar :
|
|
21
|
Zhang SL and Liu L: microRNA-148a inhibits
hepatocellular carcinoma cell invasion by targeting
sphingosine-1-phosphate receptor 1. Exp Ther Med. 9:579–584.
2015.PubMed/NCBI
|
|
22
|
Joshi P, Jeon YJ, Laganà A, Middleton J,
Secchiero P, Garofalo M and Croce CM: MicroRNA-148a reduces
tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc
Natl Acad Sci USA. 112:8650–8655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Wen Z, Liu S, Liu Y, Li X, Ge Y
and Li S: MicroRNA-148a inhibits the proliferation and promotes the
paclitaxel-induced apoptosis of ovarian cancer cells by targeting
PDIA3. Mol Med Rep. 12:3923–3929. 2015.PubMed/NCBI
|
|
24
|
Takagi S, Nakajima M, Mohri T and Yokoi T:
Post-transcriptional regulation of human pregnane X receptor by
micro-RNA affects the expression of cytochrome P450 3A4. J Biol
Chem. 283:9674–9680. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zuo J, Xia J, Ju F, Yan J, Zhu A, Jin S,
Shan T and Zhou H: MicroRNA-148a can regulate runt-related
transcription factor 3 gene expression via modulation of DNA
methyltransferase 1 in gastric cancer. Mol Cells. 35:313–319. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tian Y, Wei W, Li L and Yang R:
Down-Regulation of miR-148a promotes metastasis by DNA methylation
and is associated with prognosis of skin cancer by targeting TGIF2.
Med Sci Monit. 21:3798–3805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takai Y, Sasaki T and Matozaki T: Small
GTP-binding proteins. Physiol Rev. 81:153–208. 2001.PubMed/NCBI
|
|
28
|
Agarwal R, Jurisica I, Mills GB and Cheng
KW: The emerging role of the RAB25 small GTPase in cancer. Traffic.
10:1561–1568. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun J, Feng X, Gao S and Xiao Z:
microRNA-338-3p functions as a tumor suppressor in human
non-small-cell lung carcinoma and targets Ras-related protein 14.
Mol Med Rep. 11:1400–1406. 2015.
|
